Genelux Corporation Common Stock (GNLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genelux Corporation Common Stock (GNLX) has a cash flow conversion efficiency ratio of -0.264x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.06 Million) by net assets ($22.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GNLX net asset quality score to measure how much of total assets are equity-financed.
Genelux Corporation Common Stock - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Genelux Corporation Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Genelux Corporation Common Stock (GNLX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Genelux Corporation Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genelux Corporation Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
0.073x |
|
Graphene Manufacturing Group Ltd
V:GMG
|
-0.208x |
|
Siam Wellness Group Public Company Limited
BK:SPA
|
0.119x |
|
Adi Sarana Armada Tbk
JK:ASSA
|
0.091x |
|
Forrester Research Inc
NASDAQ:FORR
|
-0.030x |
|
Selectquote Inc
NYSE:SLQT
|
0.074x |
|
GoldMoney Inc
TO:XAU
|
0.050x |
|
Tectonic Metals Inc
V:TECT
|
-0.483x |
Annual Cash Flow Conversion Efficiency for Genelux Corporation Common Stock (2019–2025)
The table below shows the annual cash flow conversion efficiency of Genelux Corporation Common Stock from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see GNLX market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $11.54 Million | $-25.27 Million | -2.189x | -170.91% |
| 2024-12-31 | $26.27 Million | $-21.23 Million | -0.808x | +22.40% |
| 2023-12-31 | $19.47 Million | $-20.27 Million | -1.041x | -1143.31% |
| 2022-12-31 | $-35.78 Million | $-3.57 Million | 0.100x | -49.82% |
| 2021-12-31 | $-33.11 Million | $-6.58 Million | 0.199x | -37.47% |
| 2020-12-31 | $-22.66 Million | $-7.21 Million | 0.318x | +9.24% |
| 2019-12-31 | $-24.81 Million | $-7.22 Million | 0.291x | -- |
About Genelux Corporation Common Stock
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a te… Read more